Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance

Stock Track

Aug 08

Shares of ANI Pharmaceuticals (ANIP) surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and an upward revision of its full-year 2025 guidance. The strong performance and optimistic outlook have sparked investor enthusiasm, driving the stock's significant pre-market gain.

ANI Pharmaceuticals reported a Q2 2025 adjusted earnings per share (EPS) of $1.80, handily beating the analyst estimate of $1.39. The company's Q2 revenue reached $211.371 million, surpassing the expected $187.797 million. This impressive performance demonstrates ANI's strong market position and effective execution of its business strategy.

Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2025 guidance. The company now expects net revenues in the range of $818-$843 million, up from previous estimates and exceeding the FactSet consensus of $791.5 million. Additionally, the adjusted EPS outlook for 2025 has been increased to $6.98-$7.35, surpassing the FactSet estimate of $6.53. These upward revisions in guidance reflect management's confidence in the company's growth trajectory and ability to deliver strong financial results throughout the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127310099"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127310099\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127310099?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127310099","market":"nz","top_or_hot":-1,"title":"Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>Shares of ANI Pharmaceuticals (ANIP) surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and an upward revision of its full-year 2025 guidance. The strong performance and optimistic outlook have sparked investor enthusiasm, driving the stock's significant pre-market gain.</p>\n\n<p>ANI Pharmaceuticals reported a Q2 2025 adjusted earnings per share (EPS) of $1.80, handily beating the analyst estimate of $1.39. The company's Q2 revenue reached $211.371 million, surpassing the expected $187.797 million. This impressive performance demonstrates ANI's strong market position and effective execution of its business strategy.</p>\n\n<p>Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2025 guidance. The company now expects net revenues in the range of $818-$843 million, up from previous estimates and exceeding the FactSet consensus of $791.5 million. Additionally, the adjusted EPS outlook for 2025 has been increased to $6.98-$7.35, surpassing the FactSet estimate of $6.53. These upward revisions in guidance reflect management's confidence in the company's growth trajectory and ability to deliver strong financial results throughout the year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-08 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of ANI Pharmaceuticals (ANIP) surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and an upward revision of its full-year 2025 guidance. The strong performance and optimistic outlook have sparked investor enthusiasm, driving the stock's significant pre-market gain.</p>\n\n<p>ANI Pharmaceuticals reported a Q2 2025 adjusted earnings per share (EPS) of $1.80, handily beating the analyst estimate of $1.39. The company's Q2 revenue reached $211.371 million, surpassing the expected $187.797 million. This impressive performance demonstrates ANI's strong market position and effective execution of its business strategy.</p>\n\n<p>Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2025 guidance. The company now expects net revenues in the range of $818-$843 million, up from previous estimates and exceeding the FactSet consensus of $791.5 million. Additionally, the adjusted EPS outlook for 2025 has been increased to $6.98-$7.35, surpassing the FactSet estimate of $6.53. These upward revisions in guidance reflect management's confidence in the company's growth trajectory and ability to deliver strong financial results throughout the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1127310099","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127310099","pubTimestamp":1754650944,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ANI Pharmaceuticals (ANIP) surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and an upward revision of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"个股赛道|ANI Pharmaceuticals盘前大涨6.49%Q2业绩强劲上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1},"content_text":"Shares of ANI Pharmaceuticals (ANIP) surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and an upward revision of its full-year 2025 guidance. The strong performance and optimistic outlook have sparked investor enthusiasm, driving the stock's significant pre-market gain.\nANI Pharmaceuticals reported a Q2 2025 adjusted earnings per share (EPS) of $1.80, handily beating the analyst estimate of $1.39. The company's Q2 revenue reached $211.371 million, surpassing the expected $187.797 million. This impressive performance demonstrates ANI's strong market position and effective execution of its business strategy.\nAdding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2025 guidance. The company now expects net revenues in the range of $818-$843 million, up from previous estimates and exceeding the FactSet consensus of $791.5 million. Additionally, the adjusted EPS outlook for 2025 has been increased to $6.98-$7.35, surpassing the FactSet estimate of $6.53. These upward revisions in guidance reflect management's confidence in the company's growth trajectory and ability to deliver strong financial results throughout the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}